Short answer
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed its Q4 2025 10-Q quarterly report on Feb 5, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $264M (up 10461.3% year over year) with net income of $31M.
Q4 2025 key financials · XBRL
- Revenue
- $264M
- +10461.3% YoY
- Net income
- $31M
- +117.8% YoY
- Operating margin
- 15.5%
- EPS (diluted)
- $0.22
- +115.8% YoY
Source: XBRL data from the ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Q4 2025 10-Q on SEC EDGAR. USD.
ARROWHEAD PHARMACEUTICALS, INC. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $264.0M for Q1 FY2026, up $261.5M YoY from $2.5M in Q1 FY2025, driven by Sarepta, Novartis, Sanofi license agreements
- Operating income $40.8M vs operating loss $(161.4)M YoY; net income $30.8M vs net loss $(173.1)M YoY; net income per diluted share $0.22 vs $(1.39)
- Best segment: License revenues from Sarepta, Novartis, Sanofi contributed major increase; no single worst segment detailed
- Cash position strengthened by $930M gross from convertible senior notes, common stock, pre-funded warrant offerings
- Management highlighted FDA NDA approval for REDEMPLO, $200M upfront from Novartis, $200M Sarepta milestone, FDA Breakthrough Therapy for plozasiran, and positive clinical trial advancements
Risk Factors
- No new risk factors added this quarter compared to fiscal 2025 10-K
- Most material risks remain consistent with those in fiscal 2025 10-K filing
- Ongoing regulatory risk from FDA approval processes and clinical trial requirements
- Operational risk from reliance on successful development of RNAi therapeutic candidates
- Financial risk linked to liquidity management given continued R&D expenses and cash burn
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ARROWHEAD PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.